Ignite Creation Date:
2025-12-24 @ 7:04 PM
Ignite Modification Date:
2026-01-02 @ 12:22 PM
Study NCT ID:
NCT04720157
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-23
First Post:
2021-01-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Prostatic Neoplasms | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lutetium-177 PSMA-617 | View |
| None | 177Lu-PSMA-617 | View |
| None | Androgen receptor-directed therapy | View |
| None | ARDT | View |
| None | Androgen Deprivation Therapy | View |
| None | ADT | View |
| None | Metastatic Hormone sensitive prostate cancer | View |
| None | mHSPC | View |
| None | Radiographic progression free survival | View |
| None | rPFS | View |
| None | Prostate-specific membrane antigen | View |
| None | PSMA | View |
| None | Gallium-68 PSMA-11 | View |
| None | 68Ga-PSMA-11 | View |
| None | Radioligand Therapy | View |
| None | RLT | View |